Hyperthermic intraoperative chemotherapy (HIOC) for Stage IVa thymic malignancy may improve 5-year disease-free survival.
hyperthermic intraoperative chemotherapy
thymectomy
thymic malignancy
Journal
Journal of surgical oncology
ISSN: 1096-9098
Titre abrégé: J Surg Oncol
Pays: United States
ID NLM: 0222643
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
revised:
08
11
2022
received:
16
02
2022
accepted:
11
11
2022
pubmed:
2
12
2022
medline:
14
2
2023
entrez:
1
12
2022
Statut:
ppublish
Résumé
Stage IVa thymic malignancy has limited treatments. This study evaluated whether hyperthermic intraoperative chemotherapy (HIOC) after radical resection of Stage IVa thymic malignancy improves survival. All patients who underwent resection, with or without HIOC, for Stage IVa thymic malignancy at a single center from 1990 to 2021 were reviewed. Thirty-four patients were identified; 22 surgery-only versus 12 surgery and HIOC (60 min cisplatin regimen 175 mg/m This retrospective cohort study treating Stage IVa thymic malignancy with radical pleurectomy, with or without HIOC, found addition of HIOC-signaled delayed recurrence and improved disease-free survival.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Stage IVa thymic malignancy has limited treatments. This study evaluated whether hyperthermic intraoperative chemotherapy (HIOC) after radical resection of Stage IVa thymic malignancy improves survival.
METHODS
METHODS
All patients who underwent resection, with or without HIOC, for Stage IVa thymic malignancy at a single center from 1990 to 2021 were reviewed.
RESULTS
RESULTS
Thirty-four patients were identified; 22 surgery-only versus 12 surgery and HIOC (60 min cisplatin regimen 175 mg/m
CONCLUSIONS
CONCLUSIONS
This retrospective cohort study treating Stage IVa thymic malignancy with radical pleurectomy, with or without HIOC, found addition of HIOC-signaled delayed recurrence and improved disease-free survival.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
734-740Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Aprile V, Bacchin D, Korasidis S, et al. Hypertermic intrathoracic chemotherapy (HITHOC) for thymoma: a narrative review on indications and results. Ann Transl Med. 2021;9(11):957. doi:10.21037/atm-20-6704
Hsu CH, Chan JK, Yin CH, Lee CC, Chern CU, Liao CI. Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States. PLoS One. 2019;14(12):e0227197. doi:10.1371/journal.pone.0227197
Rich AL. Epidemiology of thymoma. J Thorac Dis. 2020;12(12):7531-7535. doi:10.21037/jtd-2019-thym-02
Detterbeck FC, Nicholson AG, Kondo K, Van Schil P, Moran C. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol. 2011;6(7 Suppl 3):S1710-S1716. doi:10.1097/JTO.0b013e31821e8cff
Ahmad U, Yao X, Detterbeck F, et al. Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg. 2015;Jan 149(1):95-101.e2. doi:10.1016/j.jtcvs.2014.09.124 Erratum in: J Thorac Cardiovasc Surg. 2016;151(4):1220.
Cardillo G, Carleo F, Giunti R, et al. Predictors of survival in patients with locally advanced thymoma and thymic carcinoma (Masaoka stages III and IVa). Eur J Cardiothorac Surg. 2010:37(4):819-823. doi:10.1016/j.ejcts.2009.11.001
Moser B, Fadel E, Fabre D, et al. Surgical therapy of thymic tumours with pleural involvement: an ESTS Thymic Working Group Project. Eur J Cardiothorac Surg. 2017;52:346-355.
Burt BM, Richards WG, Lee HS, et al. A phase I trial of surgical resection and intraoperative hyperthermic cisplatin and gemcitabine for pleural mesothelioma. J Thorac Oncol. 2018;13(9):1400-1409. doi:10.1016/j.jtho.2018.04.032
Belcher E, Hardwick T, Lal R, Marshall S, Spicer J, Lang-Lazdunski L. Induction chemotherapy, cytoreductive surgery and intraoperative hyperthermic pleural irrigation in patients with stage IVA thymoma. Interact Cardiovasc Thorac Surg. 2011;12(5):744-748. doi:10.1510/icvts.2010.255307
Kodama K, Higashiyama M, Okami J, et al. Cytoreductive surgery and post-operative heated pleural chemotherapy for the management of pleural surface malignancy. Int J Hyperthermia. 2013;29(7):653-662. doi:10.3109/02656736.2013.829247
Maury JM, Girard N, Tabutin M, et al. Intra-thoracic chemo-hyperthermia for pleural recurrence of thymoma. Lung Cancer. 2017;108:1-6. doi:10.1016/j.lungcan.2017.02.014
Ambrogi MC, Korasidis S, Lucchi M, et al. Pleural recurrence of thymoma: surgical resection followed by hyperthermic intrathoracic perfusion chemotherapy: table 1. Eur J Cardiothorac Surg. 2016;49(1):321-326. doi:10.1093/ejcts/ezv039
Yellin A, Simansky DA, Ben-Avi R, et al. Resection and heated pleural chemoperfusion in patients with thymic epithelial malignant disease and pleural spread: a single-institution experience. J Thorac Cardiovasc Surg. 2013;145(1):83-89. doi:10.1016/j.jtcvs.2012.10.013
Lee H-S, Jang H-J, Lo EM, et al. Povidone-iodine results in rapid killing of thymic epithelial tumour cells through cellular fixation. Interact Cardiovasc Thorac Surg. 2019;28:353-359.
Aprile V, Bacchin D, Korasidis S, et al. Surgical treatment of pleural recurrence of thymoma: is hyperthermic intrathoracic chemotherapy worthwhile. Interact Cardiovasc Thorac Surg. 2020;30:765-772.
Wolf AS, Alam NZ, Flores RM. Pleurectomy and Decortication for Malignant Pleural Diseases. In: Sugarbaker DJ, Bueno R, Burt BM, et al, eds. Sugarbaker's Adult Chest Surgery, 3e. McGraw Hill; 2020. https://accesssurgery-mhmedical-com
Clavien PA, Barkun J, de Oliveira ML, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187-196. doi:10.1097/SLA.0b013e3181b13ca2
De León LE, Bravo-Iñiguez CE, Fox S, et al. Routine surveillance for diagnosis of venous thromboembolism after pleurectomy for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2020;160(4):1064-1073. doi:10.1016/j.jtcvs.2019.12.115